BNB Plus Corp. (BNBX)
| Market Cap | 3.08M +156.9% |
| Revenue (ttm) | 1.83M -12.5% |
| Net Income | -70.57M |
| EPS | -44.63 |
| Shares Out | 5.67M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 110,540 |
| Open | 0.5490 |
| Previous Close | 0.5294 |
| Day's Range | 0.4992 - 0.5490 |
| 52-Week Range | 0.4510 - 13.9500 |
| Beta | 0.70 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 14, 2026 |
About BNBX
BNB Plus Corp. provides digital asset treasury services. The company offers real-time data tracking of treasury performance and market indicators. The company, through its subsidiaries, also develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) in the Americas, Europe, Asia, and internationally. The company engages in the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and nucleic acid production solutions for the biopharmaceutica... [Read more]
Financial Performance
In fiscal year 2025, BNB Plus's revenue was $2.14 million, an increase of 1.11% compared to the previous year's $2.11 million. Losses were -$69.49 million, 861.7% more than in 2024.
Financial StatementsNews
BNB Plus Transcript: EGM 2026
Stockholders approved granting the board authority for a reverse stock split at a ratio between 1-for-5 and 1-for-30, and also approved the adjournment proposal. Both measures passed with a majority of votes, and final results will be filed with the SEC.
BNB Plus Corp. Completes Historic $1.2 Million LineaDNA™ Order
NEW YORK--(BUSINESS WIRE)--BNB Plus Corp. (Nasdaq: BNBX) ("BNB Plus" or the "Company"), today announced that its biopharmaceutical subsidiary, LineaRx, Inc. ("LineaRx"), has successfully completed pro...
BNB Plus Corp. Announces Review of Strategic Alternatives to Maximize Shareholder Value
NEW YORK--(BUSINESS WIRE)--BNB Plus Corp. (Nasdaq: BNBX) ("BNB Plus" or the "Company"), a Nasdaq-listed digital asset treasury company focused on Binance's BNB token, today announced that its Board of...
BNB Plus Corp. Announces European Patent Grant for Fundamental Technology Underlying its Linea™ IVT Platform
NEW YORK--(BUSINESS WIRE)--BNB Plus Corp. (Nasdaq: BNBX) ("BNBX" or the "Company"), announced today that its biopharmaceutical subsidiary, LineaRx, Inc. ("LineaRx"), has been granted a European patent...
BNB Plus Corp. (BNBX) Receives Two New Orders for LineaDNA™ from Genetic Medicine Developers
NEW YORK--(BUSINESS WIRE)--BNB Plus Corp. (Nasdaq: BNBX) ("BNBX" or the "Company") today announced that its biopharmaceutical subsidiary, LineaRx, Inc. ("LineaRx"), has received two new orders for Lin...
BNB Plus Corp. (BNBX) Appoints James Haft as Independent Board Director
NEW YORK--(BUSINESS WIRE)--BNB Plus Corp. (Nasdaq: BNBX) ("BNBX" or the "Company"), today announced the appointment of James Haft as an Independent Director and member of the Board's Nominating Commit...
BNB Plus Transcript: Fintech & DATS Investor Conference
BNBX leverages four non-directional yield strategies on BNB to target 9%-12% annualized returns, combining long BNB exposure with compounding yield. The approach offers a unique way to access Binance’s growth and earnings, with robust risk management and operational transparency.
BNB Plus Transcript: Digital Asset Treasury Virtual Investor Conference
BNB Plus outlined its BNB-focused digital asset treasury strategy, leveraging unique yield opportunities and deflationary tokenomics to target 8%-12% annualized returns. The company has restructured its legacy DNA business for profitability and is exploring M&A to scale.
BNB Plus Corp. (BNBX) to Present at the Digital Asset Virtual Investor Conference January 27th
NEW YORK--(BUSINESS WIRE)--BNB Plus Corp. (Nasdaq: BNBX) ("BNBX" or the "Company"), today announced that Chief Investment Officer Patrick Horsman, CFA and Chairman of the Board Joshua Kruger will pres...
BNB Plus Corp. (BNBX) Receives $1.2M Accelerated LineaDNA™ Order
NEW YORK--(BUSINESS WIRE)--BNB Plus Corp. (Nasdaq: BNBX) (“BNBX” or the “Company”), today announced that it has received a $1.2M USD order for LineaDNA, representing the largest LineaDNA order in Comp...
BNB Plus Corp. (BNBX) Announces Largest Ever Shipment of LineaDNATM
NEW YORK--(BUSINESS WIRE)--BNB Plus Corp. (Nasdaq: BNBX) (“BNBX” or the “Company”), today announced that it has successfully manufactured and shipped the largest single LineaDNA order in Company histo...
BNB Plus Provides BNB Treasury and Operational Updates
NEW YORK--(BUSINESS WIRE)--BNB Plus Corp. (Nasdaq: BNBX) (“BNBX” or the “Company”), today provided a corporate update highlighting its recent strategic treasury growth, expected significant narrowing ...
Applied DNA Rebrands as BNB Plus Corp., Elects Josh Kruger as Chairman of the Board
STONY BROOK, N.Y.--(BUSINESS WIRE)--Applied DNA Sciences, Inc. (NASDAQ: BNBX) (the “Company”) today announced that it will change its name to BNB Plus Corp. (“BNB Plus”), reflecting the Company's comm...
BNBX Launches Digital Asset Treasury Dashboard and Provides Corporate Update
STONY BROOK, N.Y.--(BUSINESS WIRE)--Applied DNA Sciences, Inc. (NASDAQ: BNBX) ( “BNBX” or the “Company”) today announced the launch of BNBX.io, which provides real-time portfolio metrics updating the ...
Applied DNA Sciences Closes up to $58 Million Private Placement; Announces Initial BNB Holdings Valued at Over $17 Million
STONY BROOK, N.Y.--(BUSINESS WIRE)--Applied DNA Sciences, Inc. (NASDAQ: BNBX) (“Applied DNA”, “BNBX” or the “Company”), a biotechnology company advancing a yield focused BNB digital asset treasury str...
Applied DNA Sciences to Begin Trading Under New Ticker ‘BNBX' Reflecting Digital Asset Treasury Strategy
STONY BROOK, N.Y.--(BUSINESS WIRE)--Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a biotechnology company advancing a yield focused BNB digital asset treasury strategy an...
Applied DNA Sciences Announces Private Placement of Up To $58 Million To Initiate BNB Treasury Strategy and BNB Native Yield Generation
STONY BROOK, N.Y.--(BUSINESS WIRE)--Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a biotechnology company focused on providing nucleic acid production solutions, today an...
Applied DNA Abstracts Selected for Poster Presentations Showcasing LineaDNA and LineaIVT Platforms at Upcoming mRNA and CAR T Industry Conferences
STONY BROOK, NY / ACCESS Newswire / September 23, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a biotechnology company focused on providing nucleic acid production...
Applied DNA Reports Third Quarter Fiscal 2025 Financial Results
STONY BROOK, NY / ACCESS Newswire / August 14, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a biotechnology company focused on providing nucleic acid production so...
Applied DNA Announces New Follow-On LineaDNA Order from Global IVD Manufacturer for Use in Cancer Diagnostic Application
STONY BROOK, NY / ACCESS Newswire / July 24, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in synthetic DNA manufacturing powered by scalable PCR platforms...
Applied DNA Regains Compliance with All Nasdaq Continued Listing Requirements
STONY BROOK, NY / ACCESS Newswire / July 7, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (the "Company"), a leader in PCR-based DNA technologies, today announced that on July 2, 2025, it received w...
Applied DNA Sharpens Strategic Focus on Synthetic DNA Manufacturing for Biotherapeutics Applications, Consolidates Operations Behind LineaRx
- Conducts 27% Workforce Reduction, Ceases Operations at Applied DNA Clinical Labs, Positions LineaRx for Growth - STONY BROOK, NY / ACCESS Newswire / June 30, 2025 / Applied DNA Sciences, Inc. (NASDA...
Applied DNA Announces Retirement of Chairperson and CEO Dr. James A. Hayward
President and COO Judy Murrah Appointed New Chairperson of the Board of Directors and CEO STONY BROOK, NY / ACCESS Newswire / June 17, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or...
Applied DNA to Resume Quarterly Investor Call Cadence Beginning with FQ3'25 Financial Results Report in Mid-August
STONY BROOK, NY / ACCESS Newswire / June 16, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced that it will resu...
Applied DNA Announces 1-For-15 Reverse Stock Split Effective June 2, 2025
STONY BROOK, NY / ACCESS Newswire / May 29, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced that it will effec...